YU28902A - Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost - Google Patents

Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost

Info

Publication number
YU28902A
YU28902A YU28902A YUP28902A YU28902A YU 28902 A YU28902 A YU 28902A YU 28902 A YU28902 A YU 28902A YU P28902 A YUP28902 A YU P28902A YU 28902 A YU28902 A YU 28902A
Authority
YU
Yugoslavia
Prior art keywords
group
hydrogen
pyridines
tetrahydro
pyridyl
Prior art date
Application number
YU28902A
Other languages
English (en)
Inventor
Marco Baroni
Bernard Bourrie
Rosanna Cardamone
Pierre Casellas
Umberto Guzzi
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9913206A external-priority patent/FR2800071B1/fr
Priority claimed from FR0008328A external-priority patent/FR2810984B1/fr
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of YU28902A publication Critical patent/YU28902A/sh
Publication of RS50399B publication Critical patent/RS50399B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A43—FOOTWEAR
    • A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
    • A43B7/00—Footwear with health or hygienic arrangements
    • A43B7/12—Special watertight footwear
    • A43B7/125—Special watertight footwear provided with a vapour permeable member, e.g. a membrane
    • A—HUMAN NECESSITIES
    • A43—FOOTWEAR
    • A43B—CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR
    • A43B9/00—Footwear characterised by the assembling of the individual parts
    • A43B9/02—Footwear stitched or nailed through
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/0009—Producing footwear by injection moulding; Apparatus therefor
    • B29D35/0018—Moulds
    • B29D35/0045—Sealing means for the mould cavity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/06—Producing footwear having soles or heels formed and joined on to preformed uppers using a moulding technique, e.g. by injection moulding, pressing and vulcanising
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/06—Producing footwear having soles or heels formed and joined on to preformed uppers using a moulding technique, e.g. by injection moulding, pressing and vulcanising
    • B29D35/061—Producing footwear having soles or heels formed and joined on to preformed uppers using a moulding technique, e.g. by injection moulding, pressing and vulcanising by injection moulding
    • B29D35/062—Producing footwear having soles or heels formed and joined on to preformed uppers using a moulding technique, e.g. by injection moulding, pressing and vulcanising by injection moulding using means to bond the moulding material to the preformed uppers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/12—Producing parts thereof, e.g. soles, heels, uppers, by a moulding technique
    • B29D35/122—Soles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/12—Producing parts thereof, e.g. soles, heels, uppers, by a moulding technique
    • B29D35/128—Moulds or apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D35/00—Producing footwear
    • B29D35/12—Producing parts thereof, e.g. soles, heels, uppers, by a moulding technique
    • B29D35/14—Multilayered parts
    • B29D35/142—Soles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/14—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor incorporating preformed parts or layers, e.g. injection moulding around inserts or for coating articles
    • B29C45/14836—Preventing damage of inserts during injection, e.g. collapse of hollow inserts, breakage
    • B29C2045/14844—Layers protecting the insert from injected material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Pronalazak se odnosi na jedinjenja formule (I) gde X predstavlja N ili CH; R1 pretstavlja atom vodonika ili halogena ili CF3 grupu; R2 i R3 nezavisno pretstavljaju atom vodonika ili metil grupu; n je O ili 1; A pretstavlja grupu formule (a) ili (b); R4 pretstavlja atom vodonika ili halogena, (C1-C4) alkil grupu, CF3 grupu, amino grupu, mono (C1-C4) alkilamino grupu ili di (C1-C4) alkilamino grupu; R5 pretstavlja atom vodonika ili halogena, (C1-C4) alkoksi grupu, (C1-C4) alkil grupu ili CF3 grupu; R6 pretstavlja atom vodonika, (C1-C4) alkil grupu ili (C1-C4) alkoksi grupu; isto kao i na njihiove soli ili solvate, na farmaceutske preparate koji ih sadrže, na postupak za njihovo dobijanje i na sintezu intermedijera u pomenutom postupku.[The invention concerns compounds of formula (I) wherein: X represents N or CH; R1 represents a hydrogen or halogen atom, or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a group of formula (a) or (b) wherein: R4 represents a hydrogen or halogen atom, a C1-C4 alkyl group, a CF3 group, an amino, mono(C1-C4)alkylamino, di(C1- C4)alkylamino; R5 represents a hydrogen or halogen atom, a (C1-C4)alkoxy group, a (C1-C4)alkyl group or a CF3 group; R6 represents a hydrogen atom, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; and their salts or solvates, pharmaceutical compositions containing them, a method for preparing them and the synthesis intermediates in said method.
YUP-289/02A 1999-10-22 2000-10-19 Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost RS50399B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9913206A FR2800071B1 (fr) 1999-10-22 1999-10-22 Tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR0008328A FR2810984B1 (fr) 2000-06-28 2000-06-28 Pyridyl-tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
YU28902A true YU28902A (sh) 2004-11-25
RS50399B RS50399B (sr) 2009-12-31

Family

ID=26212500

Country Status (35)

Country Link
US (1) US6509351B1 (sh)
EP (1) EP1226137B8 (sh)
JP (1) JP4831908B2 (sh)
KR (1) KR100755115B1 (sh)
CN (1) CN1158276C (sh)
AR (1) AR026188A1 (sh)
AT (1) ATE271554T1 (sh)
AU (1) AU778306B2 (sh)
BG (1) BG65564B1 (sh)
BR (1) BR0014871A (sh)
CA (1) CA2386417C (sh)
CZ (1) CZ301566B6 (sh)
DE (1) DE60012355T2 (sh)
DK (1) DK1226137T3 (sh)
EA (1) EA004508B1 (sh)
EE (1) EE05055B1 (sh)
ES (1) ES2223594T3 (sh)
HK (1) HK1046532B (sh)
HR (1) HRP20020347B1 (sh)
HU (1) HUP0204444A3 (sh)
IL (2) IL149250A0 (sh)
IS (1) IS2308B (sh)
ME (1) MEP25108A (sh)
MX (1) MXPA02003979A (sh)
NO (1) NO322596B1 (sh)
NZ (1) NZ518112A (sh)
PL (1) PL198421B1 (sh)
PT (1) PT1226137E (sh)
RS (1) RS50399B (sh)
SI (1) SI1226137T1 (sh)
SK (1) SK287098B6 (sh)
TR (1) TR200201075T2 (sh)
TW (1) TWI224097B (sh)
UA (1) UA72934C2 (sh)
WO (1) WO2001029026A1 (sh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823748B1 (fr) * 2001-04-20 2004-02-20 Sanofi Synthelabo Tetrahydropyridyl-alkyl-benzodiazines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2840896B1 (fr) * 2002-06-18 2005-04-08 Sanofi Synthelabo Phenyl-et pyridyl-piperazines, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2005016910A1 (ja) 2003-08-18 2005-02-24 Sankio Chemical Co., Ltd. ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法
FR2883285B1 (fr) * 2005-03-17 2007-05-18 Sanofi Aventis Sa Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991061A (en) * 1975-07-16 1976-11-09 G. D. Searle & Co. Azanaphthaleneacetic acid derivatives
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US5118691A (en) * 1990-09-20 1992-06-02 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
US5045550A (en) * 1990-09-20 1991-09-03 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
JP2001511764A (ja) * 1996-04-12 2001-08-14 住友製薬株式会社 ピペリジニルピリミジン誘導体
US5776939A (en) * 1997-06-12 1998-07-07 Eli Lilly And Company Drug resistance and multidrug resistance modulators
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
SK287098B6 (sk) 2009-12-07
AR026188A1 (es) 2003-01-29
CN1158276C (zh) 2004-07-21
EP1226137B1 (fr) 2004-07-21
HUP0204444A3 (en) 2004-07-28
HRP20020347B1 (en) 2010-10-31
RS50399B (sr) 2009-12-31
US6509351B1 (en) 2003-01-21
KR100755115B1 (ko) 2007-09-04
EA004508B1 (ru) 2004-04-29
AU778306B2 (en) 2004-11-25
EP1226137B8 (fr) 2004-12-15
HK1046532A1 (en) 2003-01-17
CN1391570A (zh) 2003-01-15
EA200200352A1 (ru) 2002-10-31
CZ301566B6 (cs) 2010-04-21
SK5282002A3 (en) 2002-08-06
BG65564B1 (bg) 2008-12-30
DK1226137T3 (da) 2004-11-22
JP4831908B2 (ja) 2011-12-07
EP1226137A1 (fr) 2002-07-31
CA2386417A1 (en) 2001-04-26
WO2001029026A1 (fr) 2001-04-26
UA72934C2 (uk) 2005-05-16
PT1226137E (pt) 2004-11-30
KR20020040904A (ko) 2002-05-30
MEP25108A (en) 2011-12-20
NO20021872D0 (no) 2002-04-19
IL149250A0 (en) 2002-11-10
TR200201075T2 (tr) 2002-11-21
NO322596B1 (no) 2006-10-30
AU7931300A (en) 2001-04-30
HUP0204444A2 (en) 2003-05-28
PL354922A1 (en) 2004-03-22
EE200200210A (et) 2003-06-16
BG106613A (en) 2003-02-28
BR0014871A (pt) 2002-06-11
SI1226137T1 (en) 2005-02-28
CA2386417C (en) 2010-09-28
TWI224097B (en) 2004-11-21
DE60012355T2 (de) 2005-12-22
IS2308B (is) 2007-10-15
NO20021872L (no) 2002-06-21
ME01727B (me) 2010-05-07
DE60012355D1 (de) 2004-08-26
MXPA02003979A (es) 2003-01-28
PL198421B1 (pl) 2008-06-30
ATE271554T1 (de) 2004-08-15
HK1046532B (zh) 2005-03-18
IS6336A (is) 2002-04-09
JP2003512370A (ja) 2003-04-02
NZ518112A (en) 2003-11-28
HRP20020347A2 (en) 2003-08-31
ES2223594T3 (es) 2005-03-01
CZ20021382A3 (cs) 2002-07-17
IL149250A (en) 2007-08-19
EE05055B1 (et) 2008-08-15

Similar Documents

Publication Publication Date Title
AU679761B2 (en) 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT1A ligands
FR2727682B1 (sh)
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
DE69831499T2 (de) Inhibitoren des nukleosid-metabolismus
AU2525801A (en) Phenoxypropanolamines, method for producing them and pharmaceutical compositionscontaining them
ZA976705B (en) Process for the synthesis of protected esters of (S)-3,4-dihydroxybutric acid.
EP0787726A4 (sh)
AU1039688A (en) 3(2h)pyridazinone, process for its preparation and antagonistic agent against srs-a containing it
MXPA02004440A (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii.
MX9800718A (es) Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
NZ505220A (en) Arylpiperazines having activity at the serotonin 1A receptor, processes for their preparation and intermediates
PT918776E (pt) Sintese total de acilfulvenos antitumorais
TW352383B (en) Hydroximic acid derivatives, processes for their preparation, and compositions comprising them
YU28902A (sh) Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost
YU51302A (sh) Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže
TW350757B (en) Benzisoxazole derivatives and pesticidal compositions containing them
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
BG104037A (en) 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
ES2004809A6 (es) Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
PT1189908E (pt) Alcaloides de indolocarbazole de um actinomiceto marinho
HU9701295D0 (en) New process for making intermediers
ES2001166A6 (es) Procedimiento para preparar nuevos prostadienoatos
HU9701294D0 (en) New process for making internmediers